SECTION I: REPORT OVERVIEW1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Drug Delivery Device for Biologics
6.3. Route of Drug Administration
6.4. Challenges Associated with Delivery of Biologics
6.5. Need for Targeted Drug Delivery
6.6. Types of Targeted Delivery Devices of Biologics
6.7. Benefits of Targeted Delivery Devices of Biologics
6.8. Concluding Remarks
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Targeted Drug Delivery Devices for Biologics: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Device
7.2.3. Analysis by Target Organ
7.2.4. Analysis by Type of Biologic Delivered
7.2.5. Analysis by Type of Therapy Delivered
7.2.6. Analysis by Route of Administration
7.2.7. Analysis by Target Therapeutic Area
7.3. Targeted Drug Delivery Device Providers: Overall Market Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
8. COMPANY PROFILES OF PROMINENT PLAYERS
8.1. Chapter Overview
8.2. Alcyone Therapeutics
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Targeted Drug Delivery Device Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. BioCardia
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Targeted Drug Delivery Device Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. ClearPint Neuro
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Targeted Drug Delivery Device Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Mercator MedSystems
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Targeted Drug Delivery Device Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. Novartis
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Targeted Drug Delivery Device Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. Smartwise
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Targeted Drug Delivery Device Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Key Winning Strategies
9. COMPANY PROFILES OF EMERGING PLAYERS
9.1. Chapter Overview
9.2. Algorae Pharmaceuticals
9.2.1. Company Overview
9.2.2. Targeted Drug Delivery Device Portfolio
9.3. Gloriana Therapeutics
9.3.1. Company Overview
9.3.2. Targeted Drug Delivery Device Portfolio
9.4. Neurotech Pharmaceuticals
9.4.1. Company Overview
9.4.2. Targeted Drug Delivery Device Portfolio
9.5. OncoSec Medical
9.5.1. Company Overview
9.5.2. Targeted Drug Delivery Device Portfolio
9.6. PharmaCyte Biotech
9.6.1. Company Overview
9.6.2. Device Portfolio
9.7. PulseSight Therapeutics
9.7.1. Company Overview
9.7.2. Targeted Drug Delivery Device Portfolio
9.8. Renishaw
9.8.1. Company Overview
9.8.2. Targeted Drug Delivery Device Portfolio
9.9. Silexion Therapeutics
9.9.1. Company Overview
9.9.2. Targeted Drug Delivery Device Portfolio
10. PROMISING THERAPEUTIC AREA FOR TARGETED DRUG DELIVERY DEVICES
10.1. Chapter Overview
10.2. Neurological Disorders
10.2.1. Stem Cell Therapies
10.2.1.1. Publication Analysis
10.2.1.1.1. Methodology
10.2.1.1.2. List of Publications
10.2.1.1.3. Analysis by Year of Publication
10.2.1.2. Grant Analysis
10.2.1.2.1. Methodology
10.2.1.2.2. List of Academic Grants
10.2.1.2.3. Analysis by Year of Grant Awarded
10.2.1.2.4. Analysis by Amount Awarded
10.2.2. Gene Therapies
10.2.2.1. Publication Analysis
10.2.2.1.1. Methodology
10.2.2.1.2. List of Publications
10.2.2.1.3. Analysis by Year of Publication
10.2.2.2. Grant Analysis
10.2.2.2.1. Methodology
10.2.2.2.2. List of Academic Grants
10.2.2.2.3. Analysis by Year of Grant Awarded
10.2.2.2.4. Analysis by Amount Awarded
10.3. Cardiovascular Disorders
10.3.1. Stem Cell Therapies
10.3.1.1. Publication Analysis
10.3.1.1.1. Methodology
10.3.1.1.2. List of Publications
10.3.1.1.3. Analysis by Year of Publication
10.3.1.2. Grant Analysis
10.3.1.2.1. Methodology
10.3.1.2.2. List of Academic Grants
10.3.1.2.3. Analysis by Year of Grant Awarded
10.3.1.2.4. Analysis by Amount Awarded
10.3.2. Gene Therapies
10.3.2.1. Publication Analysis
10.3.2.1.1. Methodology
10.3.2.1.2. List of Publications
10.3.2.1.3. Analysis by Year of Publication
10.3.2.2. Grant Analysis
10.3.2.2.1. Methodology
10.3.2.2.2. List of Academic Grants
10.3.2.2.3. Analysis by Year of Grant Awarded
10.3.2.2.4. Analysis by Amount Awarded
11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Targeted Drug Delivery Devices: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Recruitment Status
11.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
11.3.4. Analysis by Trial Registration Year and Trial Recruitment Status
11.3.5. Analysis by Trial Phase
11.3.6. Analysis of Enrolled Patient Population by Trial Phase
11.3.7. Analysis by Study Design
11.3.8. Analysis by Type of Sponsor / Collaborator
11.3.9. Analysis by Therapeutic Area
11.3.10. Analysis by Type of Therapy
11.3.11. Leading Players: Analysis by Number of Registered Trials
11.3.12. Analysis by Geography
11.3.13. Analysis by Trial Recruitment Status and Geography
11.3.14. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography
12. LIKELY DRUG CANDIDATES
12.1. Chapter Overview
12.2. Key Parameters and Scoring Criteria
12.3. Gene Therapy Drug Candidates
12.3.1. Most Likely Drug Candidates for Delivery Via Targeted Drug Delivery Device
12.3.2. Likely Drug Candidates for Delivery Via Targeted Drug Delivery Device
12.3.3. Less Likely Drug Candidates for Delivery Via Targeted Drug Delivery Device
12.3.4. Least Likely Drug Candidates for Delivery Via Targeted Drug Delivery Device
12.4. Stem Cell Therapy Drug Candidates
12.4.1. Most Likely Drug Candidates for Delivery Via Targeted Drug Delivery Device
12.4.2. Likely Drug Candidates for Delivery Via Targeted Drug Delivery Device
12.4.3. Less Likely Drug Candidates for Delivery Via Targeted Drug Delivery Device
12.4.4. Least Likely Drug Candidates for Delivery Via Targeted Drug Delivery Device
13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion
14. GLOBAL TARGETED DRUG DELIVERY DEVICE MARKET
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Targeted Drug Delivery Device Market, Forecasted Estimates (2026- 2035)
14.3.1. Scenario Analysis
14.3.2. Conservative Scenario
14.3.3. Optimistic Scenario
14.4. Key Market Segmentations
15. TARGETED DRUG DELIVERY DEVICE MARKET, BY TYPE OF DEVICE
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Targeted Drug Delivery Device Market: Distribution by Type of Device
15.3.1. Targeted Drug Delivery Device Market for Cannulas, Forecasted Estimates (Till 2035)
15.3.2. Targeted Drug Delivery Device Market for Catheters, Forecasted Estimates (Till 2035)
15.3.3. Targeted Drug Delivery Device Market for Other Devices, Forecasted Estimates (Till 2035)
15.4. Data Triangulation and Validation
16. TARGETED DRUG DELIVERY DEVICE MARKET, BY TARGET ORGAN
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Targeted Drug Delivery Market: Distribution by Target Organ
16.3.1. Targeted Drug Delivery Device Market for Breast, Forecasted Estimates (Till 2035)
16.3.2. Targeted Drug Delivery Device Market for Brain, Forecasted Estimates (Till 2035)
16.3.3. Targeted Drug Delivery Device Market for Heart, Forecasted Estimates (Till 2035)
16.3.4. Targeted Drug Delivery Device Market for Eyes, Forecasted Estimates (Till 2035)
16.4. Data Triangulation and Validation
17. TARGETED DRUG DELIVERY DEVICE MARKET, BY TYPE OF THERAPY DELIVERED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Targeted Drug Delivery Market: Distribution by Type of Therapy Delivered
17.3.1. Targeted Drug Delivery Device Market for Immunotherapies, Forecasted Estimates (Till 2035)
17.3.2. Targeted Drug Delivery Device Market for Gene Therapies, Forecasted Estimates (Till 2035)
17.3.3. Targeted Drug Delivery Device Market for Cell Therapies, Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation
18. TARGETED DRUG DELIVERY DEVICE MARKET, BY ROUTE OF ADMINISTRATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Targeted Drug Delivery Market: Distribution by Route of Administration
18.3.1. Targeted Drug Delivery Device Market for Intratumoral, Forecasted Estimates (Till 2035)
18.3.2. Targeted Drug Delivery Device Market for Transendocardial, Forecasted Estimates, (Till 2035)
18.3.3. Targeted Drug Delivery Device Market for Others, Forecasted Estimates (Till 2035)
18.4. Data Triangulation and Validation
19. TARGETED DRUG DELIVERY DEVICE MARKET, BY THERAPEUTIC AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Targeted Drug Delivery Market: Distribution by Therapeutic Area
19.3.1. Targeted Drug Delivery Device Market for Oncological Disorders, Forecasted Estimates (Till 2035)
19.3.2. Targeted Drug Delivery Device Market for Cardiovascular Disorders, Forecasted Estimates (Till 2035)
19.3.3. Targeted Drug Delivery Device Market for Neurological Disorders, Forecasted Estimates (Till 2035)
19.3.4. Targeted Drug Delivery Device Market for Ophthalmic Disorders, Forecasted Estimates (Till 2035)
19.4. Data Triangulation and Validation
20. TARGETED DRUG DELIVERY DEVICE MARKET, BY KEY GEOGRAPHICAL REGIONS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Targeted Drug Delivery Market: Distribution by Key Geographical Regions
20.3.1. Targeted Drug Delivery Device Market in North America, Forecasted Estimates (Till 2035)
20.3.2. Targeted Drug Delivery Device Market in Europe, Forecasted Estimates (Till 2035)
20.3.3. Targeted Drug Delivery Device Market in Asia-Pacific, Forecasted Estimates (Till 2035)
20.4. Market Dynamics Assessment
20.4.1. Penetration Growth (P-G) Matrix
20.4.2. Data Triangulation and Validation
21. TARGETED DRUG DELIVERY DEVICE MARKET, BY LEADING DEVELOPERS
21.1. Chapter Overview
21.2. Targeted Drug Delivery Device Market: Distribution by Leading Developers
22. TARGETED DRUG DELIVERY DEVICE MARKET, SALES FORECAST OF DEVICES
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Targeted Drug Delivery Devices Market for Biologics: Sales Forecast
22.3.1. Alcyone's MEMS Cannula: Sales Forecast
22.3.2. Electro-Transfection Injection System: Sales Forecast
22.3.3. Helix Biotherapeutic Delivery System: Sales Forecast
22.3.4. ImmunoPulse: Sales Forecast
22.3.5. SmartFlow Neuro Ventricular Cannula: Sales Forecast
24. EXECUTIVE INSIGHTS
24.1. Seraxis
24.1.1. Company Snapshot
24.1.2. Interview Transcript: William Rust, Founder and Chief Executive Officer
24.2. Defymed
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Manuel Pires, Junior Business Developer
24.3. University of Texas at San Antonio
24.3.1. Organization Snapshot
24.3.2. Interview Transcript: Lyle Hood, Assistant Professor
24.4. Massachusetts Institute of Technology
24.4.1. Organization Snapshot
24.4.2. Interview Transcript: Anonymous, Postdoctoral Associate
LIST OF FIGURES
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lesson Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Clinical Trial Analysis
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Popular Drug Delivery Devices
Figure 6.2 Most Prominent Routes of Drug Administration for Biologics
Figure 7.1 Targeted Drug Delivery Devices: Distribution by Status of Development
Figure 7.2 Targeted Drug Delivery Devices: Distribution by Type of Device
Figure 7.3 Targeted Drug Delivery Devices: Distribution by Target Organ
Figure 7.4 Targeted Drug Delivery Devices: Distribution by Type of Biologic Delivered
Figure 7.5 Targeted Drug Delivery Devices: Distribution by Type of Therapy Delivered
Figure 7.6 Targeted Drug Delivery Devices: Distribution by Route of Administration
Figure 7.7 Targeted Drug Delivery Devices: Distribution by Target Therapeutic Area
Figure 7.8 Targeted Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 7.9 Targeted Drug Delivery Device Developers: Distribution by Company Size
Figure 7.10 Targeted Drug Delivery Device Developers: Distribution by Location of Headquarters (Region)
Figure 7.11 Targeted Drug Delivery Device Developers: Distribution by Location of Headquarters (Country)
Figure 8.1 BioCardia: Annual Revenues, FY 2021 onwards (USD Million)
Figure 8.2 ClearPoint Neuro: Annual Revenues, FY 2021 onwards (USD Million)
Figure 8.3 Novartis: Annual Revenues, FY 2021 onwards (USD Million)
Figure 10.1 Stem Cell Therapy for Neurological Disorders, Publication Analysis: Distribution by Year of Publication, Since 2015
Figure 10.2 Stem Cell Therapy for Neurological Disorders, Grant Analysis: Distribution by Year of Grant Awarded, Since 2015
Figure 10.3 Stem Cell Therapy for Neurological Disorders, Grant Analysis, Distribution by Cumulative Amount Awarded (USD Million), Since 2015
Figure 10.4 Gene Therapy for Neurological Disorders, Publication Analysis: Distribution by Year of Publication, Since 2015
Figure 10.5 Gene Therapy for Neurological Disorders, Grant Analysis: Distribution by Year of Grant Awarded, Since 2015
Figure 10.6 Gene Therapy for Neurological Disorders, Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), Since 2015
Figure 10.7 Stem Cell Therapy for Cardiovascular Disorders, Publication Analysis: Distribution by Year of Publication, Since 2015
Figure 10.8 Stem Cell Therapy for Cardiovascular Disorders, Grant Analysis: Distribution by Year of Grant Awarded, Since 2015
Figure 10.9 Stem Cell Therapy for Cardiovascular Disorders, Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), Since 2015
Figure 10.10 Gene Therapy for Cardiovascular Disorders, Publication Analysis: Distribution by Year of Publication, 2015-2024
Figure 10.11 Gene Therapy for Cardiovascular Disorders, Grant Analysis: Distribution by Year of Grant Awarded, Since 2015
Figure 10.12 Gene Therapy for Cardiovascular Disorders, Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), Since 2015
Figure 11.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2018
Figure 11.2 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 11.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Since 2018
Figure 11.4 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 11.7 Clinical Trial Analysis: Distribution by Study Design
Figure 11.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 11.10 Clinical Trial Analysis: Distribution by Type of Therapy
Figure 11.11 Leading Players: Distribution by Number of Registered Trials
Figure 11.12 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 11.13 Clinical Trial Analysis: Distribution by Trial Recruitment Status and Geography
Figure 11.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Figure 14.1 Global Targeted Drug Delivery Device Market, Forecasted Estimates (Till 2035) (USD Million)
Figure 14.2 Global Targeted Drug Delivery Device Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
Figure 14.3 Global Targeted Drug Delivery Device Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
Figure 15.1 Targeted Drug Delivery Device Market: Distribution by Type of Device
Figure 15.2 Targeted Drug Delivery Device Market for Catheters, Forecasted Estimates (Till 2035) (USD Million)
Figure 15.3 Targeted Drug Delivery Device Market for Cannulas, Forecasted Estimates (Till 2035) (USD Million)
Figure 15.4 Targeted Drug Delivery Device Market for Other Devices, Forecasted Estimates (Till 2035) (USD Million)
Figure 16.1 Targeted Drug Delivery Device Market: Distribution by Target Organ
Figure 16.2 Targeted Drug Delivery Device Market for Brain, Forecasted Estimates (Till 2035) (USD Million)
Figure 16.3 Targeted Drug Delivery Device Market for Breast, Forecasted Estimates (Till 2035) (USD Million)
Figure 16.4 Targeted Drug Delivery Device Market for Eyes, Forecasted Estimates (Till 2035) (USD Million)
Figure 16.5 Targeted Drug Delivery Device Market for Heart, Forecasted Estimates (Till 2035) (USD Million)
Figure 17.1 Targeted Drug Delivery Device Market: Distribution by Type of Therapy Delivered
Figure 17.2 Targeted Drug Delivery Device Market for Cell Therapies, Forecasted Estimates (Till 2035) (USD Million)
Figure 17.3 Targeted Drug Delivery Device Market for Gene Therapies, Forecasted Estimates (Till 2035) (USD Million)
Figure 17.4 Targeted Drug Delivery Device Market for Immunotherapies, Forecasted Estimates (Till 2035) (USD Million)
Figure 18.1 Targeted Drug Delivery Device Market: Distribution by Route of Administration Delivered
Figure 18.2 Targeted Drug Delivery Device Market for Intratumoral, Forecasted Estimates (Till 2035) (USD Million)
Figure 18.3 Targeted Drug Delivery Device Market for Transendocardial, Forecasted Estimates (Till 2035) (USD Million)
Figure 18.4 Targeted Drug Delivery Device Market for Others, Forecasted Estimates (Till 2035) (USD Million)
Figure 19.1 Targeted Drug Delivery Device Market: Distribution by Therapeutic Area
Figure 19.2 Targeted Drug Delivery Device Market for Cardiovascular Disorders, Forecasted Estimates (Till 2035) (USD Million)
Figure 19.3 Targeted Drug Delivery Device Market for Neurological Disorders, Forecasted Estimates (Till 2035) (USD Million)
Figure 19.4 Targeted Drug Delivery Device Market for Oncological Disorders, Forecasted Estimates (Till 2035) (USD Million)
Figure 19.5 Targeted Drug Delivery Device Market for Ophthalmic Disorders, Forecasted Estimates (Till 2035) (USD Million)
Figure 20.1 Targeted Drug Delivery Device Market: Distribution by Key Geographical Regions
Figure 20.2 Targeted Drug Delivery Device Market in North America, Forecasted Estimates (Till 2035) (USD Million)
Figure 20.3 Targeted Drug Delivery Device Market in Europe, Forecasted Estimates (Till 2035) (USD Million)
Figure 20.4 Targeted Drug Delivery Device Market in Asia-Pacific, Forecasted Estimates (Till 2035) (USD Million)
Figure 21.1 Targeted Drug Delivery Device Market: Distribution by Leading Developers, Current Year (USD Million)
Figure 21.2 Targeted Drug Delivery Device Market: Distribution by Leading Developers, 2035 (USD Million)
Figure 22.1 Targeted Drug Delivery Device Market: Alcyone's MEMS Cannula Sales Forecast, Till 2035 (USD Million)
Figure 22.2 Targeted Drug Delivery Device Market: Electro-Transfection Injection System Sales Forecast, Till 2035 (USD Million)
Figure 22.3 Targeted Drug Delivery Device Market: Helix Biotherapeutic Delivery System Sales Forecast, Till 2035 (USD Million)
Figure 22.4 Targeted Drug Delivery Device Market: ImmunoPulse Sales Forecast, Till 2035 (USD Million)
Figure 22.5 Targeted Drug Delivery Device Market: SmartFlow Neuro Ventricular Cannula Sales Forecast, Till 2035 (USD Million)
Figure 23.1 Concluding Remarks: Market Landscape
Figure 23.2 Concluding Remarks: Clinical Trial Analysis
Figure 23.3 Concluding Remarks: Market Forecast and Opportunity Analysis (1/2)
Figure 23.4 Concluding Remarks: Market Forecast and Opportunity Analysis (2/2)
LIST OF TABLES
Table 7.1 Targeted Drug Delivery Devices: Information on Developer, Status of Development and Type of Device
Table 7.2 Targeted Drug Delivery Devices: Information on Target Organ, Type of Biologic Delivered and Type of Therapy Delivered
Table 7.3 Targeted Drug Delivery Devices: Information on Route of Administration and Therapeutic Area
Table 7.4 Targeted Drug Delivery Devices for Biologics: List of Developers
Table 8.1 Targeted Drug Delivery Device Developers: List of Prominent Companies Profiled
Table 8.2 Alcyone Therapeutics: Company Overview
Table 8.3 Alcyone Therapeutics: Device Portfolio
Table 8.4 BioCardia: Company Overview
Table 8.5 BioCardia: Targeted Drug Delivery Device Portfolio
Table 8.6 BioCardia: Recent Developments and Future Outlook
Table 8.7 ClearPoint Neuro: Company Overview
Table 8.8 ClearPoint Neuro: Targeted Drug Delivery Device Portfolio
Table 8.9 ClearPoint Neuro: Recent Developments and Future Outlook
Table 8.10 Mercator MedSystems: Company Overview
Table 8.11 Mercator MedSystems: Targeted Drug Delivery Device Portfolio
Table 8.12 Novartis: Company Overview
Table 8.13 Novartis: Targeted Drug Delivery Device Portfolio
Table 8.14 Novartis: Recent Developments and Future Outlook
Table 8.15 Smartcella: Company Overview
Table 8.16 SmartCella: Targeted Drug Delivery Device Portfolio
Table 8.17 Smartcella: Recent Developments and Future Outlook
Table 9.1 Targeted Drug Delivery Device Developers: List of Emerging Companies Profiled
Table 9.2 Algorae Pharmaceuticals: Company Overview
Table 9.3 Algorae Pharmaceuticals: Targeted Drug Delivery Device Portfolio
Table 9.4 BioCardia: Company Overview
Table 9.5 BioCardia: Targeted Drug Delivery Device Portfolio
Table 9.6 Gloriana Therapeutics: Company Overview
Table 9.7 Gloriana Therapeutics: Targeted Drug Delivery Device Portfolio
Table 9.8 Neurotech Pharmaceuticals: Company Overview
Table 9.9 Neurotech Pharmaceuticals: Targeted Drug Delivery Device Portfolio
Table 9.10 OncoSec: Company Overview
Table 9.11 OncoSec: Targeted Drug Delivery Device Portfolio
Table 9.12 PharmaCyte Biotech: Company Overview
Table 9.13 PharmaCyte Biotech: Targeted Drug Delivery Device Portfolio
Table 9.14 PulseSight Therapeutics: Company Overview
Table 9.15 PulseSight Therapeutics: Targeted Drug Delivery Device Portfolio
Table 9.16 Renishaw: Company Overview
Table 9.17 Renishaw: Targeted Drug Delivery Device Portfolio
Table 9.18 Silexion Therapeutics: Company Overview
Table 9.19 Silexion Therapeutics: Targeted Drug Delivery Device Portfolio
Table 10.1 Stem Cell Therapies for Neurological Disorders: List of Approved / Under Development Therapies
Table 10.2 Stem Cell Therapies for Neurological Disorders: List of Publications, Since 2015
Table 10.3 Stem Cell Therapies for Neurological Disorders: List of Academic Grants, Since 2015
Table 10.4 Gene Therapies for Neurological Disorders: List of Approved / Under Development Therapies
Table 10.5 Gene Therapies for Neurological Disorders: List of Publications, Since 2015
Table 10.6 Gene Therapies for Neurological Disorders: List of Academic Grants, Since 2015
Table 10.7 Stem Cell Therapies for Cardiovascular Disorders: List of Approved / Under Development Therapies
Table 10.8 Stem Cell Therapies for Cardiovascular Disorders: List of Publications, Since 2015
Table 10.9 Stem Cell Therapies for Cardiovascular Disorders: List of Academic Grants, Since 2015
Table 10.10 Gene Therapies for Cardiovascular Disorders: List of Approved / Under Development Therapies
Table 10.11 Gene Therapies for Cardiovascular Disorders: List of Publications, Since 2015
Table 10.12 Gene Therapies for Cardiovascular Disorders: List of Academic Grants, Since 2015
Table 12.1 Gene Therapy: Most Likely Candidates for Delivery via Targeted Drug Delivery Device
Table 12.2 Gene Therapy: Likely Candidates for Delivery via Targeted Drug Delivery Device
Table 12.3 Gene Therapy: Less Likely Candidates for Delivery via Targeted Drug Delivery Device
Table 12.4 Gene Therapy: Least Likely Candidates for Delivery via Targeted Drug Delivery Device
Table 12.5 Stem Cell Therapy: Most Likely Candidates for Delivery via Targeted Drug Delivery Device
Table 12.6 Stem Cell Therapy: Likely Candidates for Delivery via Targeted Drug Delivery Device
Table 12.7 Stem Cell Therapy: Less Likely Candidates for Delivery via Targeted Drug Delivery Device
Table 12.8 Stem Cell Therapy: Least Likely Candidates for Delivery via Targeted Drug Delivery Device
Table 12.9 Stem Cell Therapy Drug Candidates: Top 10 Drugs for Delivery via Targeted Drug Delivery Devices
Table 12.10 Gene Therapy Drug Candidates: Top 10 Drugs for Delivery via Targeted Drug Delivery Devices
Table 24.1 Seraxis: Key Highlights
Table 24.2 Defymed: Key Highlights
Table 24.3 University of Texas: Key Highlights
Table 24.4 Massachusetts Institute of Technology: Key Highlights
Table 25.1 Targeted Drug Delivery Devices: Distribution by Status of Development
Table 25.2 Targeted Drug Delivery Devices: Distribution of Type of Device
Table 25.3 Targeted Drug Delivery Devices: Distribution by Target Organ
Table 25.4 Targeted Drug Delivery Devices: Distribution by Type of Biologic Delivered
Table 25.5 Targeted Drug Delivery Devices: Distribution by Type of Therapy Delivered
Table 25.6 Targeted Drug Delivery Devices: Distribution by Route of Administration
Table 25.7 Targeted Drug Delivery Devices: Distribution by Target Therapeutic Area
Table 25.8 Targeted Drug Delivery Device Developers: Distribution by Year of Establishment
Table 25.9 Targeted Drug Delivery Device Developers: Distribution by Company Size
Table 25.10 Targeted Drug Delivery Device Developers: Distribution by Location of Headquarters (Region)
Table 25.11 Targeted Drug Delivery Device Developers: Distribution by Location of Headquarters (Country)
Table 25.12 BioCardia: Annual Revenues, FY 2021 onwards (USD Million)
Table 25.13 ClearPoint Neuro: Annual Revenues, FY 2021 onwards (USD Million)
Table 25.14 Novartis: Annual Revenues, FY 2021 onwards (USD Million)
Table 25.15 Stem Cell Therapy for Neurological Disorders, Publication Analysis: Distribution by Year of Publication, Since 2015
Table 25.16 Stem Cell Therapy for Neurological Disorders, Grant Analysis: Distribution by Year of Grant Awarded, Since 2015
Table 25.17 Stem Cell Therapy for Neurological Disorders, Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), Since 2015
Table 25.18 Gene Therapy for Neurological Disorders, Publication Analysis: Distribution by Year of Publication, Since 2015
Table 25.19 Gene Therapy for Neurological Disorders, Grant Analysis: Distribution by Year of Grant Awarded, Since 2015
Table 25.20 Gene Therapy for Neurological Disorders, Grant Analysis: Distribution by Cumulative Amount Granted, Since 2015 (USD Million)
Table 25.21 Stem Cell Therapy for Cardiovascular Disorders, Publication Analysis: Distribution by Year of Publication, Since 2015
Table 25.22 Stem Cell Therapy for Cardiovascular Disorders, Grant Analysis: Distribution by Year of Grant Awarded, Since 2015
Table 25.23 Stem Cell Therapy for Cardiovascular Disorders, Grant Analysis: Distribution by Cumulative Amount Granted, Since 2015 (USD Million)
Table 25.24 Gene Therapy for Cardiovascular Disorders, Publication Analysis: Distribution by Year of Publication, Since 2015
Table 25.25 Gene Therapy for Cardiovascular Disorders, Grant Analysis: Distribution by Year of Grant Awarded, Since 2015
Table 25.26 Gene Therapy for Cardiovascular Disorders, Grant Analysis: Distribution by Cumulative Amount Granted (USD Million)
Table 25.27 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2018
Table 25.28 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 25.29 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Since 2018
Table 25.30 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Table 25.31 Clinical Trial Analysis: Distribution by Trial Phase
Table 25.32 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.33 Clinical Trial Analysis: Distribution by Study Design
Table 25.34 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.35 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 25.36 Clinical Trial Analysis: Distribution by Type of Therapy
Table 25.37 Leading Players: Distribution by Number of Registered Trials
Table 25.38 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.39 Clinical Trial Analysis: Distribution by Trial Recruitment Status and Geography
Table 25.40 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Recruitment Status and Geography
Table 25.41 Global Targeted Drug Delivery Device Market, Forecasted Estimates (Till 2035) (USD Million)
Table 25.42 Global Targeted Drug Delivery Device Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
Table 25.43 Global Targeted Drug Delivery Device Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
Table 25.44 Targeted Drug Delivery Device Market: Distribution by Type of Device
Table 25.45 Targeted Drug Delivery Device Market for Cannulas, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.46 Targeted Drug Delivery Device Market for Catheters, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.47 Targeted Drug Delivery Device Market for Other Devices, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.48 Targeted Drug Delivery Device Market: Distribution by Target Organ
Table 25.49 Targeted Drug Delivery Device Market for Breast, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.50 Targeted Drug Delivery Device Market for Brain, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.51 Targeted Drug Delivery Device Market for Heart, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.52 Targeted Drug Delivery Device Market for Eyes, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.53 Targeted Drug Delivery Device Market: Distribution by Type of Therapy Delivered
Table 25.54 Targeted Drug Delivery Device Market for Immunotherapies, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.55 Targeted Drug Delivery Device Market for Gene Therapies, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.56 Targeted Drug Delivery Device Market for Cell Therapies, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.57 Targeted Drug Delivery Device Market: Distribution by Route of Administration Delivered
Table 25.58 Targeted Drug Delivery Device Market for Intratumoral, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.59 Targeted Drug Delivery Device Market for Transendocardial, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.60 Targeted Drug Delivery Device Market for Others, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.61 Targeted Drug Delivery Device Market: Distribution by Therapeutic Area Delivered
Table 25.62 Targeted Drug Delivery Device Market for Oncological Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.63 Targeted Drug Delivery Device Market for Cardiovascular Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.64 Targeted Drug Delivery Device Market for Neurological Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.65 Targeted Drug Delivery Device Market for Ophthalmic Disorders, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.66 Targeted Drug Delivery Device Market: Distribution by Key Geographical Regions
Table 25.67 Targeted Drug Delivery Device Market in North America, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.68 Targeted Drug Delivery Device Market in Europe, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.69 Targeted Drug Delivery Device Market in Asia-Pacific, Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.70 Targeted Drug Delivery Device Market: Distribution by Leading Targeted Drug Delivery Developers (based on sales of targeted drug delivery devices in the current year (USD Million))
Table 25.71 Targeted Drug Delivery Device Market: Distribution by Leading Targeted Drug Delivery Developers (based on sales of targeted drug delivery devices in the year 2035 (USD Million))
Table 25.72 Targeted Drug Delivery Device Market: Alcyone's MEMS Cannula (AMCTM) Sales Forecast, (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.73 Targeted Drug Delivery Device Market: Electro-Transfection Injection System Sales Forecast, (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.74 Targeted Drug Delivery Device Market: Helix Biotherapeutic Delivery System Sales Forecast, (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.75 Targeted Drug Delivery Device Market: ImmunoPulse Sales Forecast, (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 25.76 Targeted Drug Delivery Device Market: SmartFlow Neuro Ventricular Cannula Sales Forecast, (Till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
